To watch the recorded session click here Universal Electrochemical Synthesis of Mesoporous Chalcogenide Semiconductors |
Novel antibody theranostics for Glypican-1 over-expressing solid tumors
My research (in collaboration with industry partner GlyTherix, Ltd., Australia) explores Miltuximab®, a clinical stage antibody that recognizes Glypican-1 (GPC-1), a heparin sulfated proteoglycan highly expressed in GBM (and other cancers) but poorly expressed in normal tissue. The ongoing project involves developing a multi-format antibody platform for GBM theranostics. The platform would include full-length Miltuximab®, Fab’2, Fab and single-chain variable fragment (scFv) as constructs with high affinity, but exhibiting variable pharmacokinetic properties. In the present study, all four formats were radiolabelled with 89Zr [zircomium-89] to validate their potential as diagnostic probes for non-invasive positron emission tomography (PET) imaging. These agents are concurrently being tested in 3D-tumour spheroids and pre-clinical mouse GBM tumour models to determine their safety and effectiveness using fluorescence and PET/CT imaging, respectively.
About Saikat:
Saikat is undertaking his PhD with CI Professor Kristofer Thurecht at the University of Queensland. Saikat is also a member of the ARC Centre for Innovation in Biomedical Imaging Technology (CIBIT). He completed his Masters from Indian Institute of Technology, Bombay (IIT-B). Saikat has experience working in academia (protein aggregation in cancer & neuro-degenerative diseases) and the biopharma industry (biosimilars and biologic drugs). Saikat will be investigating the therapeutic and diagnostic applications of novel antibodies in oncology.
About AIBN Seminar Series
The AIBN Seminar series showcases a range of seminars across different topics and disciplines
Join The Network
Stay on top of our industry news and developments, events and opportunities, by joining The Network
Sign up today